- ￥700 - 2200
- 齐源
- 100303
- 国产/进口
- 2025年07月13日
- FC, IHC-F
- 仓鼠
- 小鼠
7 年钻石会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 供应商：
齐源
- 库存：
999
- 靶点：
CD3ε
- 级别：
CD3ε Antibody
- 目录编号：
CD3ε Antibody
- 克隆性：
单克隆
- 抗原来源：
仓鼠
- 保质期：
CD3ε Antibody
- 抗体英文名：
Biotin anti-mouse CD3ε Antibody
- 抗体名：
CD3ε Antibody
- 标记物：
CD3ε Antibody
- 宿主：
仓鼠
- 适应物种：
小鼠
- 免疫原：
CD3ε Antibody
- 亚型：
CD3ε Antibody
- 形态：
CD3ε Antibody
- 应用范围：
FC, IHC-F
- 保存条件：
2-8℃
- 浓度：
0.5 mg/ml
- 规格：
50 µg/500 µg
| 规格： | 50 µg | 产品价格： | ￥700.0 |
|---|---|---|---|
| 规格： | 500 µg | 产品价格： | ￥2200.0 |
Biotin anti-mouse CD3ε Antibody详细如下：
Description ：CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Igsuperfamily and primarily expressed on T cells, NK-T cells, and at different levels onthymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with theCD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCRsignal transduction, T cell activation, and antigen recognition by binding the peptide/MHCantigen complex.
Verified Reactivity ：Mouse
Antibody Type ：Monoclonal
Host Species ：Armenian Hamster
Immunogen ：H-2K -specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation ：Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation ：The antibody was purified by affinity chromatography, and conjugated with biotin under optimalconditions.
Concentration ：0.5 mg/ml
Storage & Handling ：The antibody solution should be stored undiluted between 2°C and 8°C. Do not freeze.
Application ：FC - Quality tested、IHC-F - Verified
Recommended Usage ：Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometricanalysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10 cellsin 100 µl. For immunohistochemistry, a concentration range of 5.0 - 10 µg/mL is suggested. It isrecommended that the reagent be titrated for optimal performance for each application.
Description ：CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Igsuperfamily and primarily expressed on T cells, NK-T cells, and at different levels onthymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with theCD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCRsignal transduction, T cell activation, and antigen recognition by binding the peptide/MHCantigen complex.
Verified Reactivity ：Mouse
Antibody Type ：Monoclonal
Host Species ：Armenian Hamster
Immunogen ：H-2K -specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation ：Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation ：The antibody was purified by affinity chromatography, and conjugated with biotin under optimalconditions.
Concentration ：0.5 mg/ml
Storage & Handling ：The antibody solution should be stored undiluted between 2°C and 8°C. Do not freeze.
Application ：FC - Quality tested、IHC-F - Verified
Recommended Usage ：Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometricanalysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10 cellsin 100 µl. For immunohistochemistry, a concentration range of 5.0 - 10 µg/mL is suggested. It isrecommended that the reagent be titrated for optimal performance for each application.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验该产品被引用文献
Application References(PubMed link indicatesBioLegend citation)：
1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
13. Ko SY, et al. 2005. J. Immunol. 175:3309.
14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
20. Guo Y, et al. 2008. Blood 112:480. PubMed
21. Kenna TJ, et al. 2008. Blood 111:2091.
22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
27. Qi Q, et al. 2009. Blood 114:564. PubMed
28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations：
1. Suzuki M, et al. 2015. J Immunol. 195: 1273-1281. PubMed
2. Doisne J, et al. 2015. J Immunol. 195: 3937 - 3945.. PubMed
3. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
4. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
5. Davis FM, et al. 2020. J Immunol. 2503:204. PubMed
6. Kim S, et al. 2020. Immunity. 53(4):759-774.e9. PubMed
7. Domingues AF, et al. 2020. Elife. 9:e51754. PubMed
8. Roco JA et al. 2019. Immunity. 51(2):337-350 . PubMed
9. Tanimura N et al. 2018. Developmental cell. 46(5):581-594 . PubMed
10. Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed
11. Lin YH, et al. 2021. Front Immunol. 12:626418. PubMed
12. Riether C, et al. 2021. Cell Reports. 34(4):108663. PubMed
1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
13. Ko SY, et al. 2005. J. Immunol. 175:3309.
14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
20. Guo Y, et al. 2008. Blood 112:480. PubMed
21. Kenna TJ, et al. 2008. Blood 111:2091.
22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
27. Qi Q, et al. 2009. Blood 114:564. PubMed
28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations：
1. Suzuki M, et al. 2015. J Immunol. 195: 1273-1281. PubMed
2. Doisne J, et al. 2015. J Immunol. 195: 3937 - 3945.. PubMed
3. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
4. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
5. Davis FM, et al. 2020. J Immunol. 2503:204. PubMed
6. Kim S, et al. 2020. Immunity. 53(4):759-774.e9. PubMed
7. Domingues AF, et al. 2020. Elife. 9:e51754. PubMed
8. Roco JA et al. 2019. Immunity. 51(2):337-350 . PubMed
9. Tanimura N et al. 2018. Developmental cell. 46(5):581-594 . PubMed
10. Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed
11. Lin YH, et al. 2021. Front Immunol. 12:626418. PubMed
12. Riether C, et al. 2021. Cell Reports. 34(4):108663. PubMed
相关实验
生物素亲和素(又称抗生物素)系统(biotin avidin system,BAS)标记抗体的技术是 20 世纪 70 年代后期发展起来的一种新的免疫检测方法。 由于亲和素与生物素间的亲和力极强，结合迅速，且极其稳定，生物素标记抗体和酶的标记率高，又不影响蛋白的活性，使 BAS 标记技术比常规酶联免疫、放射免疫及荧光免疫技术有着更高的灵敏度，为微量抗原、抗体的检测开辟了新的途径。近年来，在 BAS 检测中多用链霉亲和素“streptavidin,SA”，它是链霉菌培养过程中的分泌物，完整的链霉
本法可使抗体或其它蛋白质的ε-氨基通过手臂与酰化的生物素共价结合。其后，生物素化的分子可应用酶标-亲和素或荧光染料-链霉亲和素复合物来检测。小分子的水溶性生物素对细菌蛋白链霉亲和素具有高度亲和力是本法的设计基础。 NHSB：N-羟基琥珀酰亚胺生物素（有商品供应） 0.1 mol/L 碳酸氢钠缓冲液，pH 8.0 双蒸水（注意去除游离氨基），用以配制碳酸氢钠缓冲液或硼酸缓冲液 DMSO（二甲亚砜，有毒试剂） 1 mol/L NH4Cl 叠氮钠（有毒试剂） PBS
本法可使抗体或其它蛋白质的ε-氨基通过手臂与酰化的生物素共价结合。其后，生物素化的分子可应用酶标-亲和素或荧光染料-链霉亲和素复合物来检测。小分子的水溶性生物素对细菌蛋白链霉亲和素具有高度亲和力是本法的设计基础。 l NHSB：N-羟基琥珀酰亚胺生物素（有商品供应） l 0.1 mol/L碳酸氢钠缓冲液，pH 8.0（见附录） l 双蒸水（注意去除游离氨基），用以配制碳酸氢钠缓冲液或硼酸缓冲液 l DMSO（二甲亚砜，有毒试剂） l 1 mol/L NH
文献支持
生物素抗小鼠 CD3ε 抗体
￥700 - 2200
